A5037412635- Sepsis Diagnosis and Treatment
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Nosocomial Infections in ICU
- Inflammation biomarkers and pathways
- Respiratory Support and Mechanisms
- Long-Term Effects of COVID-19
- Inflammasome and immune disorders
- Pneumonia and Respiratory Infections
- COVID-19 Impact on Reproduction
- Immune responses and vaccinations
- Tuberculosis Research and Epidemiology
- Neonatal and Maternal Infections
- Hemodynamic Monitoring and Therapy
- Respiratory viral infections research
- Streptococcal Infections and Treatments
- Autoimmune and Inflammatory Disorders Research
- Hematological disorders and diagnostics
- Neonatal Respiratory Health Research
- Immune Response and Inflammation
- Mosquito-borne diseases and control
- Multiple Sclerosis Research Studies
- Adrenal Hormones and Disorders
- Bacterial Identification and Susceptibility Testing
- Pneumocystis jirovecii pneumonia detection and treatment
National and Kapodistrian University of Athens
2016-2024
University General Hospital Attikon
2021-2023
Copenhagen University Hospital
2021
Université de Montpellier
2021
Hôpital de la Conception
2021
Aix-Marseille Université
2021
Assistance Publique Hôpitaux de Marseille
2021
Istituto Giannina Gaslini
2021
Istituti di Ricovero e Cura a Carattere Scientifico
2021
Athens Medical Center
2021
Abstract Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is indicative increased risk progression coronavirus disease 2019 (COVID-19) to respiratory failure. The SAVE-MORE double-blind, randomized controlled trial evaluated the efficacy and safety anakinra, an IL-1α/β inhibitor, in 594 patients with COVID-19 at progressing failure as identified by plasma suPAR ≥6 ng ml −1 , 85.9% ( n = 510) whom were receiving dexamethasone. At day 28, adjusted...
A subanalysis of a randomized clinical trial indicated sepsis survival benefit from interleukin (IL)-1 blockade in patients with features the macrophage activation-like syndrome (MALS). This study aimed to investigate frequency MALS and develop biomarker diagnosis prognosis. Patients infections systemic inflammatory response were assigned one test cohort (n = 3417) validation 1704). was diagnosed for scoring positive either hemophagocytic score and/or having both hepatobiliary dysfunction...
It was studied if early suPAR-guided anakinra treatment can prevent severe respiratory failure (SRF) of COVID-19.A total 130 patients with suPAR ≥6 ng/ml were assigned to subcutaneous 100 mg once daily for 10 days. Primary outcome SRF incidence by day 14 defined as any ratio below 150 mmHg necessitating mechanical or non-invasive ventilation. Main secondary outcomes 30-day mortality and inflammatory mediators; 28-day WHO-CPS explored. Propensity-matched standard-of care comparators...
The state of immune activation may guide targeted immunotherapy in sepsis. In a double-blind, double-dummy randomized clinical study, 240 patients with sepsis due to lung infection, bacteremia, or acute cholangitis were subjected measurements serum ferritin and HLA-DR/CD14. Patients macrophage activation-like syndrome (MALS) immunoparalysis treatment anakinra recombinant interferon-gamma placebo. Twenty-eight-day mortality was the primary endpoint; classification secondary endpoint. Using...
Since the Sepsis-3 criteria, change in Sequential Organ Failure Assessment (SOFA) score has become a key component of sepsis identification. Thus, it could be argued that reversal this (ΔSOFA) may reflect response and used as measure efficacy interventional trials. We aimed to assess predictive performance ΔSOFA for 28-day mortality.Data from two previously published randomized controlled trials were studied: first reporting on patients with severe Gram-negative infections derivation cohort...
Rationale: Although early antimicrobial discontinuation guided by procalcitonin (PCT) has shown decreased antibiotic consumption in lower respiratory tract infections, the outcomes long-term sepsis sequelae remain unclear.Objectives: To investigate if PCT guidance may reduce incidence of infection-associated adverse events sepsis.Methods: In this multicenter trial, 266 patients with (by Sepsis-3 definitions) acute pyelonephritis, or primary bloodstream infection were randomized (1:1) to...
Abstract Background Endotype classification may guide immunomodulatory management of patients with bacterial and viral sepsis. We aimed to identify immune endotypes transitions associated response anakinra (human interleukin 1 receptor antagonist) in participants the SAVE-MORE trial. Methods Adult hospitalized radiological findings PCR-confirmed severe pneumonia caused by SARS-CoV-2 plasma-soluble urokinase plasminogen activator levels ≥ 6 ng/ml trial (NCT04680949) were characterized at...
The epidemiology of severe lower respiratory tract infections (LRTI) is constantly changing. We aimed to describe it using the BioFire
Abstract We aimed to develop presepsin as a marker of diagnosis severe infections either bacterial and viral origin. The derivation cohort was recruited from 173 hospitalized patients with acute pancreatitis or post-operative fever infection suspicion aggravated by at least one sign the quick sequential organ failure assessment (qSOFA). first validation 57 admissions emergency department qSOFA second 115 COVID-19 pneumonia. Presepsin measured in plasma PATHFAST assay. Concentrations more...
ABSTRACT We aimed to evaluate heparin-binding protein (HBP) as a marker of prognosis unfavorable outcome in COVID-19 pneumonia. This was post hoc analysis the SAVE clinical trial investigating anakinra treatment, guided by suPAR (soluble urokinase plasminogen activator receptor) levels ≥6 ng/mL, for prevention severe respiratory failure hospitalized patients with Baseline HBP plasma were measured 534 fluorescence dry quantitative immunoassay using Jet-iStar 800 analyzer. Concentrations...
Pulmonary endothelium dysfunction is a key characteristic of ARDS. The aim this study was to investigate endothelium-derived markers, such as angiopoietin-2 (Ang-2) and endothelial cell-specific molecule-1 (endocan), at the vascular alveolar compartments outcome predictors in Fifty-three consecutive ARDS patients were studied. primary 28-day mortality. Secondary endpoints days unassisted ventilation with organ failure other than ARDS, during period. Nonsurvivors presented higher lung injury...
Elevated concentrations of soluble urokinase plasminogen activator receptor (suPAR) predict progression to severe respiratory failure (SRF) or death among patients with COVID-19 pneumonia and guide early anakinra treatment. As suPAR testing may not be routinely available in every health-care setting, alternative biomarkers are needed. We investigated the performance C-reactive protein (CRP), interferon gamma-induced protein-10 (IP-10) TNF-related apoptosis-inducing ligand (TRAIL) for...
We report about the first imported case of Chikungunya fever in Greece a Greek traveler returning from Dominican Republic and associated public health response. investigated performed focused epidemiological entomological investigation all areas patient visited during infectious period, to identify targeted interventions needed. Entomological revealed occurrence competent vector Aedes albopictus (Diptera: Culicidae) environment surrounding hospital where was admitted her workplace. All...
ABSTRACT Introduction The management of pneumonia caused by SARS-CoV-2 should rely on early recognition the risk for progression to severe respiratory failure (SRF) and its prevention. We investigated if suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF. Methods In this open-label prospective trial, 130 patients admitted with levels ≥6 μg/l were assigned subcutaneous 100mg once daily 10 days. primary outcome was incidence...